Browsing by Author "Buddhist Tzu-Chi General Hospital Taiwan"

Filter results by typing the first few letters
Now showing 1 - 4 of 4
  • No Thumbnail Available
    PublicationMetadata only
    Efficacy, Immunogenicity, and Safety of a 9-Valent Human Papillomavirus Vaccine: Subgroup Analysis of Participants from Asian Countries
    (2018-06-05) S. M. Garland; P. Pitisuttithum; H. Y.S. Ngan; C. H. Cho; C. Y. Lee; C. A. Chen; Y. C. Yang; T. Y. Chu; N. F. Twu; R. Samakoses; Y. Takeuchi; T. H. Cheung; S. C. Kim; L. M. Huang; B. G. Kim; Y. T. Kim; K. H. Kim; Y. S. Song; S. Lalwani; J. H. Kang; M. Sakamoto; H. S. Ryu; N. Bhatla; H. Yoshikawa; M. C. Ellison; S. R. Han; E. Moeller; S. Murata; M. Ritter; M. Sawata; C. Shields; A. Walia; G. Perez; A. Luxembourg; Ibaraki Prefectural Central Hospital; Bharati Vidyapeeth Medical College, Pune; National Taiwan University Hospital; Keimyung University (KU), College of Medicine; Chang Gung Memorial Hospital; Ewha Womans University School of Medicine; Mackay Memorial Hospital Taiwan; University of Melbourne; Buddhist Tzu-Chi General Hospital Taiwan; Jikei University; SungKyunKwan University, School of Medicine; Seoul National University; Veterans General Hospital-Taipei; Mahidol University; All India Institute of Medical Sciences, New Delhi; Merck & Co., Inc.; Phramongkutklao College of Medicine; The University of Hong Kong; University of Ulsan, College of Medicine; The Catholic University of Korea; Chinese University of Hong Kong; Ajou University; MSD K.K.; Fukui General Hospital
    © The Author(s) 2018. Published by Oxford University Press for the Infectious Diseases Society of America. Background A 9-valent human papillomavirus-6/11/16/18/31/33/45/52/58 (9vHPV) vaccine extends coverage to 5 next most common oncogenic types (31/33/45/52/58) in cervical cancer versus quadrivalent HPV (qHPV) vaccine. We describe efficacy, immunogenicity, and safety in Asian participants (India, Hong Kong, South Korea, Japan, Taiwan, and Thailand) from 2 international studies: a randomized, double-blinded, qHPV vaccine-controlled efficacy study (young women aged 16-26 years; NCT00543543; Study 001); and an immunogenicity study (girls and boys aged 9-15 years; NCT00943722; Study 002). Methods Participants (N = 2519) were vaccinated at day 1 and months 2 and 6. Gynecological samples (Study 001 only) and serum were collected for HPV DNA and antibody assessments, respectively. Injection-site and systemic adverse events (AEs) were monitored. Data were analyzed by country and vaccination group. Results 9vHPV vaccine prevented HPV-31/33/45/52/58-related persistent infection with 90.4%-100% efficacy across included countries. At month 7, ≥97.9% of participants seroconverted for each HPV type. Injection-site AEs occurred in 77.7%-83.1% and 81.9%-87.5% of qHPV and 9vHPV vaccine recipients in Study 001, respectively, and 62.4%-85.7% of girls/boys in Study 002; most were mild to moderate. Conclusions The 9vHPV vaccine is efficacious, immunogenic, and well tolerated in Asian participants. Data support 9vHPV vaccination programs in Asia. Clinical Trials Registration NCT00543543; NCT00943722.
  • No Thumbnail Available
    PublicationMetadata only
    Inflammatory characteristics of rhBMP-2 in vitro and in an in vivo rodent model
    (2011-02-01) Kwang Bok Lee; Cyrus E. Taghavi; Kyung Jin Song; Chananit Sintuu; Jeong Hyun Yoo; Gun Keorochana; Shia Tzu Tzeng; Zhiqiang Fei; Jen Chung Liao; Jeffrey C. Wang; University of California, Los Angeles; Chonbuk National University, School of Medicine; Mahidol University; Buddhist Tzu-Chi General Hospital Taiwan; Chang Gung Memorial Hospital
    Study Design.: In vivo and in vitro model. Objective.: Investigate soft-tissue inflammation caused by rhBMP-2. Summary of Background Data.: Although rhBMP-2 produces excellent rates of fusion in the spine, dysphagia and respiratory compromise have occurred when used in the neck. The mechanism of the swelling and inflammatory response has yet to be fully elucidated. Methods.: ELISA kits (IL-6, IL-10, TNF-α) were used to measure cytokine levels at different concentrations of rhBMP-2. Absorbable collagen sponges were implanted with or without different concentrations of rhBMP-2 into the backs of rats subcutaneously (SC) and intramuscularly (IM). Magnetic resonance imaging was used to measure inflammation at 3 hours and 2, 4, and 7 days. The inflammatory volumes were measured and compared using MIPAV software. Rats were killed after 7 days and studied. Results.: IL-6, IL-10, and TNF-α release was dose-dependent. Soft-tissue edema after rhBMP-2 implantation was also dose-dependent, peaking at 3 hours SC, after SC and IM implantations, and on day 2 IM after IM implantation. All formed a granuloma-type mass after SC insertion. The mass was much larger in the 10 and 20 μg/10 μL (high-concentration) groups. The inflammatory response did not diffuse across physiologic barriers (subcutaneous fascia). Both high-dose groups were associated with encapsulated hematomas and a significant increase in the inflammatory zone. Conclusion.: Swelling and inflammation after rhBMP-2 use are dose-dependent. Swelling may be due to direct contact as well as spread in the plane of access. The causes are a robust inflammatory reaction as well as sterile seroma and encapsulated hematoma formation. Copyright © 2011 Lippincott Williams & Wilkins. Unauthorized reproduction of this article is prohibited.
  • No Thumbnail Available
    PublicationMetadata only
    Longevity, tumor, and physical vitality in rats consuming ginsenoside Rg1
    (2021-01-01) Chao Chieh Hsieh; Chiung Yun Chang; Tania Xu Yar Lee; Jinfu Wu; Suchada Saovieng; Yu Wen Hsieh; Maijian Zhu; Chih Yang Huang; Chia Hua Kuo; Tzu Chi University of Science and Technology; University of Taipei; Asia University; China Medical University Hospital; Buddhist Tzu-Chi General Hospital Taiwan; Mahidol University; China Medical University; South China Normal University
    Background: Effects of the major ginsenoside Rg1 on mammalian longevity and physical vitality are rarely reported. Purpose: To examine longevity, tumor, and spontaneous locomotor activity in rats consuming Rg1. Methods: A total of 138 Wistar rats were randomized into 2 groups: control (N = 69) and Rg1 (N = 69). Rg1 (0.1 mg/kg per day) were orally supplemented from 6 months of age until natural death. Spontaneous mobility was measured by video-tracking together with body composition (dual energy x-ray absorptiometry) and inflammation markers at 5, 14, 21, and 28 months of age. Results: No significant differences in longevity (control: 706 days; Rg1: 651 days, p = 0.77) and tumor incidence (control: 19%; Rg1: 12%, p = 0.24) were observed between the two groups. Movement distance in the control group declined significantly by ∼60% at 21 months of age, together with decreased TNF-α (p = 0.01) and increased IL-10 (p = 0.02). However, the movement distance in the Rg1 group was maintained ∼50% above the control groups (p = 0.01) at 21 months of age with greater magnitudes of TNF-α decreases and IL-10 increases. Glucose, insulin, and body composition (bone, muscle and fat percentages) were similar for both groups during the entire observation period. Conclusion: The results of the study suggest a delay age-dependent decline in physical vitality during late life by lifelong Rg1 consumption. This improvement is associated with inflammatory modulation. Significant effects of Rg1 on longevity and tumorigenesis were not observed.
  • No Thumbnail Available
    PublicationMetadata only
    Lower tumorigenesis without life extension in rats receiving lifelong deep ocean minerals
    (2020-01-01) Suchada Saovieng; Jinfu Wu; Wei Horng Jean; Chih Yang Huang; Matthew F. Higgins; Ahmad Alkhatib; Mallikarjuna Korivi; Chiao Nan Chen; Chia Hua Kuo; Tzu Chi University of Science and Technology; University of Taipei; National Yang-Ming University Taiwan; Far Eastern Memorial Hospital Taiwan; China Medical University Hospital Taichung; Teesside University; Buddhist Tzu-Chi General Hospital Taiwan; Tzu Chi University; University of Derby; Mahidol University; China Medical University Taichung; South China Normal University; Zhejiang Normal University
    © 2020 The Authors. Cancer Medicine published by John Wiley & Sons Ltd. Naturally occurring tumor in animals receiving high minerals from deep oceans (DOM: hardness 600 mg/L) from 6 months of age until natural death was firstly assessed in 200 Sprague Dawley rats, randomized into four groups: Control (C), DOM (D), Fructose (F), and Fructose + DOM (FD). Fructose drink contained 11% fructose. Tumor incidence (necropsy at death) in the D group was ~40% lower than that in the C group (P <.05), together with lower body mass gain and greater locomotive activity during their initial 18 months (P <.05) but not during later life. X-ray image analysis on abnormal solid tissue among survivors at 18 and 24 months of age confirms a similar trend, exhibiting ~50% and ~65% lower tumor incidence than the C and F groups, respectively. Reduced-to-oxidized glutathione ratio (GSH/GSSG) declined with age for the first three quarters of life on all groups (P <.05), followed by a resurgence during end-life among survivors at 24 months. This resurgence is markedly associated with lower tumor expansion but unrelated with DOM supplementation. Our results demonstrate valuable application of minerals and trace elements from deep oceans, as a vastly available natural source, on tumor suppression during normal aging.